

Applicant(s):	Michael W. Miller	:	Group Art Unit: To be assigned
Serial No.:	To be assigned	:	Examiner: To be assigned
Filed:	To be assigned	:	
For:	CCR5 Antagonists Useful For Treating AIDS	:	Attorney Docket No. : IN01415K1B
		:	
		X	

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Pursuant to Rule 56, it is requested that the documents listed on the accompanying PTO-1449 Form be considered and made of record in the above-identified patent application. Copy(ies) of these references ☐ are attached ☒ were filed in related application U.S. Serial No(s) **10/107,940** filed **March 27, 2002**, respectively.

☐ This Information Disclosure Statement is being filed within three (3) months of the filing date of the application.

☒ This Information Disclosure Statement is being concurrently filed with the above-identified application.

☐ This Information Disclosure Statement is being concurrently filed with a Request for Continued Examination (RCE).

☐ This Information Disclosure Statement is being filed prior to the mailing of a first Office Action on the merits.

☐ Each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement; or

☐ No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of this Information Disclosure Statement; or


40953 1.DOC

- (d) ☐ This Information Disclosure Statement is being filed on or before the payment of the issue fee; and
- ☐ Each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement; or
- ☐ No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of this Information Disclosure Statement; and
- ☐ The Commissioner is hereby authorized to charge the requisite fee listed on the attached Fee Transmittal Sheet.
- ☐ The Commissioner is hereby authorized to charge any additional fees which may be required for this Information Disclosure Statement, or credit any overpayment to Deposit Account No. **19-0365**, Patent Case No. **IN01415K1B**. A DUPLICATE COPY OF THIS SHEET IS ATTACHED.

Respectfully submitted,
SCHERING-PLOUGH CORPORATION

Dated: **February 6, 2004**
SCHERING-PLOUGH CORPORATION
Patent Department, K-6-1, 1990
2000 Galloping Hill Road
Kenilworth, NJ 07033-0530
Facsimile No.: (908) 298-5388

By: _____


Name: **Anita W. Magatti**
Reg. No.: **29.825**
Attorney of Record
Telephone No.: (908) 298-5067

FORM PTO-1449		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: IN01415K1B		SERIAL NO.: To be assigned	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICANT: Michael W. Miller			
(Use several sheets if necessary)				FILING DATE: To be assigned		GROUP: To be assigned	

U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE	
	AA	5,883,096	3/16/99	Lowe et al	514		
	AB	5,889,006	3/30/99	Lowe et al	519		
	AC	6,037,352	3/14/00	Lowe et al	514		
	AD	5,952,349	9/14/99	Asberom et al	514		
	AE	5,977,138	11/2/99	Wang et al	514		
	AF	6,066,636	5/23/00	Kozlowski et al	514		

FOREIGN PATENT DOCUMENTS								
DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION			
AL	WO 00/66559	11/9/00	WIPO		YES	NO		
AM	WO 00/66558	11/9/00	WIPO					
AN	WO 99/04794	2/4/99	WIPO					
AO	WO 97/24324	7/10/97	WIPO					
AP	WO 97/16440	5/9/97	WIPO					
BL	WO 94/18192	8/18/94	WIPO					
BM	1 103 276	6/28/00	Europe					

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)	
AQ	Vandamme et al, <u>Antiviral Chemistry and Chemotherapy</u> , <u>9</u> (1998) p. 187-203
AR	Connor et al, <u>Virology</u> , <u>206</u> (1995) p. 935-944
AS	Plater-Zyberk et al, <u>Immunol. Let.</u> , <u>57</u> (1997) p. 117-120
AT	Boiardi et al, <u>Clinical and Experimental Rheumatology</u> , <u>17</u> , (1999) p. 419-425
AU	Hatano et al, <u>Clin. Exp. Immunol.</u> , <u>117</u> (1999) p. 237-243
AV	Raychaudhuri et al, <u>International J. of Immunopharmacology</u> , <u>20</u> (1998) p. 661-667
AW	Chihara et al, <u>J. Allergy Clin. Immunol.</u> , <u>100</u> , 6, part 2 (1997) p. S52-S55
AX	Beck et al, <u>J. Immunol.</u> , <u>159</u> , 6 (1997) p. 2962-72
AY	Tagat et al, <u>Bioorganic & Medicinal Chemistry Letters</u> , <u>11</u> (2001) 2143-2146.

EXAMINER	DATE CONSIDERED
----------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.